Tainá M Marques Selected Research

VS 215

4/2022

Serum GFAP differentiates Alzheimer's disease from frontotemporal dementia and predicts MCI-to-dementia conversion.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Tainá M Marques Research Topics

Disease

3	Parkinson Disease (Parkinson's Disease) 11/2021 - 12/2017
2	Multiple System Atrophy 11/2021 - 12/2017
2	Parkinsonian Disorders (Parkinsonism) 11/2021 - 07/2019
1	Dementia (Dementias) 04/2022
1	Gliosis 04/2022
1	Cognitive Dysfunction 04/2022
1	Cerebral Amyloid Angiopathy (Congophilic Angiopathy) 01/2022
1	Progressive Supranuclear Palsy (Steele Richardson Olszewski Syndrome) 11/2021
1	Cerebellar Ataxia (Dysmetria) 12/2017
1	Movement Disorders (Movement Disorder) 12/2017
1	Tauopathies 01/2017
1	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2017
1	Synucleinopathies 01/2017
1	Disease Progression 01/2017

Drug/Important Bio-Agent (IBA)

5	Biomarkers (Surrogate Marker)IBA 04/2022 - 01/2017
1	VS 215IBA 04/2022
1	Glial Fibrillary Acidic ProteinIBA 04/2022
1	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 01/2022
1	Plasminogen Activators (Plasminogen Activator)IBA 01/2022
1	Peptides (Polypeptides)IBA 11/2021
1	Proteins (Proteins, Gene)FDA Link 11/2021
1	Galectin 1 (LGALS1)IBA 07/2019
1	MicroRNAs (MicroRNA)IBA 12/2017